Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 305

Sort by

Sort Order Select

Journal Articles

Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency

Blood (2019) 134 (Supplement_1): 949.

https://doi.org/10.1182/blood-2019-125352

Published: 2019

Journal Articles

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Farrukh Shah, MDMBBS,FRCPath, Paul Telfer, DM, FRCP, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, MD, Joe Hickey, PhD, Clark Paramore, MPH, Minesh Jobanputra, MD, Kate Ryan, MD

Blood (2019) 134 (Supplement_1): 3550.

https://doi.org/10.1182/blood-2019-129930

Published: 2019

Journal Articles

Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)

Omar Niss, MD, Robert B. Lorsbach, MD PhD, David K. Buchbinder, MD MSHS, Satheesh Chonat, MD, Morgan L. McLemore, MD, Timothy McCavit, MD, Jeffrey H Schwartz, MD, Jessica Meznarich, MD, Katie Seu, Wenying Zhang, MD PhD, Theodosia A. Kalfa, MD PhD

Blood (2019) 134 (Supplement_1): 3521.

https://doi.org/10.1182/blood-2019-128975

Published: 2019

Journal Articles

Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency

Blood (2019) 134 (Supplement_1): 2175.

https://doi.org/10.1182/blood-2019-123069

Published: 2019

Journal Articles

ZNF802 (JAZF1), a Possible New Therapeutic Target for Treatment of β-Thalassemia

Chokdee Wongborisuth, MSc, Amornrat Tangprasittipap, PhD, Usanarat Anurathapan, MD, Nuankanya Sathirapongsasuti, MD, PhD, Orapan Sripichai, PhD, Duantida Songdej, Suradej Hongeng, MD

Blood (2019) 134 (Supplement_1): 3546.

https://doi.org/10.1182/blood-2019-127678

Published: 2019

Journal Articles

Low Dose of Eltrombopag with Long-Term Response in Children with Severe Aplastic Anemia, Less Morbi-Mortality Better Quality of Life

Norma C Lopez-Santiago, MD, Rogelio a Paredes Aguilera, MD, Angelica Cecilia Monsivais Orozco, MD, Maria De Lourdes Gonzalez Pedroza, MD, Gabriela Tavera Rodriguez, MD, Mara Toscano, MD

Blood (2019) 134 (Supplement_1): 5026.

https://doi.org/10.1182/blood-2019-130832

Published: 2019

Journal Articles

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Drorit Grizim Merkel, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Ohad Benjamini, MD, Yaron Davidovitz, MD, Orly Goitein, MD

Blood (2019) 134 (Supplement_1): 5432.

https://doi.org/10.1182/blood-2019-125279

Published: 2019

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Journal Articles

Review of Therapeutic Erythrocytapheresis in Patients with Thalassemia Major

Erika Wall, MD, Lauren Bolster, MD

Blood (2019) 134 (Supplement_1): 1176.

https://doi.org/10.1182/blood-2019-126809

Published: 2019

Journal Articles

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Annika Kasprzak, Kathrin Nachtkamp, MD, Mustafa Kondakci, MD, Thomas Schroeder, MD, Guido Kobbe, MD, Andrea Kündgen, MD, Jennifer Kaivers, MD, Christina Rautenberg, MD, Rainer Haas, MD, Norbert Gattermann, MD, Nicolas Bonadies, MD, Ulrich Germing, MD

Blood (2019) 134 (Supplement_1): 4250.

https://doi.org/10.1182/blood-2019-124512

Published: 2019

Journal Articles

Barriers and Facilitators to Chronic Red Cell Transfusion Therapy for Children with Sickle Cell Anemia: Results from the Displace Consortium

Alyssa M Schlenz, PhD, Shannon Phillips, PhD RN, Martina Mueller, PhD, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS

Blood (2019) 134 (Supplement_1): 4697.

https://doi.org/10.1182/blood-2019-130646

Published: 2019

Journal Articles

Pancreatic Iron Deposition Following the Role of Iron Loading Among Transfusion Dependent Sickle Cell Disease Egyptian Children and Young Adults

Mohsen Saleh Elalfy, MD, Khalid Allam, MD, Ahmed Ibrahim, MD, Basant Mosaad, MD, Fatma Soliman Elsayed Ebeid, MD

Blood (2019) 134 (Supplement_1): 4828.

https://doi.org/10.1182/blood-2019-123683

Published: 2019

Journal Articles

Transfusion-Induced Impairment of Macrophage Responses Is Partially Restored By the Iron Chelator Deferasirox

Francesca Vinchi, PhD, Richard Sparla, Sara Passos, PhD, Heike Weidner, Martina Rauner, PhD, Uwe Platzbecker, Martina U. Muckenthaler, PhD

Blood (2018) 132 (Supplement 1): 3625.

https://doi.org/10.1182/blood-2018-99-113016

Published: 2018

Journal Articles

Thalassemia Management Checklists: Quick Reference Guides to Reduce Disparities in the Care of Patients with Transfusion-Dependent Thalassemia

Ashutosh Lal, MD, Sujit Sheth, MD, Sandra Gilbert, PhD, Janet L. Kwiatkowski, MD

Blood (2018) 132 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2018-99-109945

Published: 2018

Journal Articles

Impact of a Ten-Year National Italian Networking on Cardiac Complications in Patients with Thalassemia Major

Alessia Pepe, MD, Laura Pistoia, Aurelio Maggio, MD, Annamaria Carrà, Maria Grazia Roberti, Pier Paolo Bitti, Rosamaria Rosso, MD, Maurizio Caniglia, Roberto Mattei, Anna Maria Petrungaro, MD, Ada Riva, Riccardo Righi, Vincenzo Positano, Antonella Meloni, PhD

Blood (2018) 132 (Supplement 1): 1055.

https://doi.org/10.1182/blood-2018-99-112546

Published: 2018

Journal Articles

A Randomized Prospective Study to Assess the Effect of Vitamin E on Peroxiredoxin- 2 As a Novel Antioxidant Marker in Young Beta-Thalassemia Major Patients on Different Chelation Therapy

Mohamed Abd el mohsen, Maha Saber, Amira Adly, Eman Ismail, Omar Elalfy, MD, Elghamry Islam, Fatma Ibrahim, Mohsen Saleh Elalfy, MD

Blood (2018) 132 (Supplement 1): 1058.

https://doi.org/10.1182/blood-2018-99-115186

Published: 2018

Journal Articles

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Simon Cheesman, Raakhee Shah, MPharm, Sara Trompeter, MD, Perla Eleftheriou, FRCPath, MRCP, Bernadette Hylton, RN, Maciej W Garbowski, MDPhD, John Porter, MA MDFRCP FRCPath

Blood (2018) 132 (Supplement 1): 1062.

https://doi.org/10.1182/blood-2018-99-119030

Published: 2018

Journal Articles

Epidemiological Study on β-Thalassemia in Algeria

Blood (2018) 132 (Supplement 1): 4902.

https://doi.org/10.1182/blood-2018-99-112812

Published: 2018

Journal Articles

Iron Chelation Therapy of Thalassemia Patients Is Still a Challenge. Single Centre Experience from United Arab Emirates

Hani Yousif Osman, MD, Khaled al Qawasmeh, Sabir Hussain, MBBS FRCP, Amar Lal, MBBS FCPS MRCP, Arif Alam, Jorgen Kristensen, MD PhD

Blood (2018) 132 (Supplement 1): 4908.

https://doi.org/10.1182/blood-2018-99-114601

Published: 2018

NARROW

Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)

Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency

ZNF802 (JAZF1), a Possible New Therapeutic Target for Treatment of β-Thalassemia

Low Dose of Eltrombopag with Long-Term Response in Children with Severe Aplastic Anemia, Less Morbi-Mortality Better Quality of Life

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Review of Therapeutic Erythrocytapheresis in Patients with Thalassemia Major

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Barriers and Facilitators to Chronic Red Cell Transfusion Therapy for Children with Sickle Cell Anemia: Results from the Displace Consortium

Pancreatic Iron Deposition Following the Role of Iron Loading Among Transfusion Dependent Sickle Cell Disease Egyptian Children and Young Adults

Transfusion-Induced Impairment of Macrophage Responses Is Partially Restored By the Iron Chelator Deferasirox

Thalassemia Management Checklists: Quick Reference Guides to Reduce Disparities in the Care of Patients with Transfusion-Dependent Thalassemia

Impact of a Ten-Year National Italian Networking on Cardiac Complications in Patients with Thalassemia Major

A Randomized Prospective Study to Assess the Effect of Vitamin E on Peroxiredoxin- 2 As a Novel Antioxidant Marker in Young Beta-Thalassemia Major Patients on Different Chelation Therapy

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Epidemiological Study on β-Thalassemia in Algeria

Iron Chelation Therapy of Thalassemia Patients Is Still a Challenge. Single Centre Experience from United Arab Emirates

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only